Quick Answer
Spyre Therapeutics, Inc. reported Operating Income Loss of -$209.56 million for the year ending 2025.
- Spyre Therapeutics, Inc. showed a decrease of -0.5% in Operating Income Loss from 2024 to 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$5.50 million | Q3 2016: -$6.30 million | Q4 2016: -$5.54 million | Q1 2017: -$6.33 million | Q2 2017: -$6.72 million | Q3 2017: -$8.00 million | Q4 2017: -$6.63 million | Q1 2018: -$8.25 million | Q2 2018: -$9.67 million | Q3 2018: -$12.24 million | Q4 2018: -$15.31 million | Q1 2019: -$17.66 million | Q2 2019: -$18.62 million | Q3 2019: -$22.15 million | Q4 2019: -$21.91 million | Q1 2020: -$19.02 million | Q2 2020: -$21.56 million | Q3 2020: -$18.12 million | Q4 2020: -$22.78 million | Q1 2021: -$18.21 million | Q2 2021: -$6.71 million | Q3 2021: -$20.29 million | Q1 2022: -$24.44 million | Q2 2022: -$22.42 million | Q3 2022: -$18.76 million | Q1 2023: -$18.81 million | Q2 2023: -$159.25 million | Q3 2023: -$18.34 million | Q1 2024: -$47.77 million | Q2 2024: -$44.15 million | Q3 2024: -$55.39 million | Q1 2025: -$53.57 million | Q2 2025: -$41.94 million | Q3 2025: -$56.89 million.
- Over the full 12 years of available data (2014 to 2025), Spyre Therapeutics, Inc.'s Operating Income Loss has declined by 2,253.6%.
- Historical annual values: Fiscal year 2025: -$209.56 million | Fiscal year 2024: -$208.57 million | Fiscal year 2023: -$242.30 million | Fiscal year 2022: -$84.78 million | Fiscal year 2021: -$65.65 million | Fiscal year 2020: -$81.48 million | Fiscal year 2019: -$80.33 million | Fiscal year 2018: -$45.46 million | Fiscal year 2017: -$27.68 million | Fiscal year 2016: -$21.91 million | Fiscal year 2015: -$11.32 million | Fiscal year 2014: -$8.90 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: